Chiba, Japan

Tooru Okayama


 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2012-2013

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tooru Okayama: Innovator in Antitumor Research

Introduction

Tooru Okayama is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds with antitumor activity. With a total of two patents to his name, Okayama's work is recognized for its potential impact on cancer treatment.

Latest Patents

Okayama's latest patents focus on tricyclic pyrazolopyrimidine derivatives. These compounds are represented by a specific formula that inhibits the function of HSP90, a chaperone protein, and demonstrates antitumor activity. His patents include a medicament comprising this compound, a pharmaceutical composition utilizing the compound, and a method for treating cancer with it. The innovative nature of these patents highlights Okayama's commitment to advancing cancer therapies.

Career Highlights

Tooru Okayama is currently employed at Daiichi Sankyo Company, Limited, where he continues to engage in groundbreaking research. His work at this esteemed pharmaceutical company allows him to collaborate with other experts in the field and contribute to the development of new medical solutions.

Collaborations

Some of Okayama's notable coworkers include Hitoshi Ohki and Masahiro Ikeda. Their collaboration fosters a dynamic research environment that enhances the potential for innovative discoveries in the pharmaceutical industry.

Conclusion

Tooru Okayama's contributions to antitumor research through his innovative patents and collaborations at Daiichi Sankyo Company, Limited, underscore his role as a significant figure in the field of pharmaceutical development. His work holds promise for improving cancer treatment options in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…